Autolus Limited

Ucl Business Plc

Martin Pulé

Shaun Cordoba

Simon Thomas

Shimobi Onuoha

Matteo Righi

James Sillibourne

Paul Maciocia

Mathieu Ferrari

Leila Mekkaoui

Lydia Lee

Kwee L Yong

Khai Kong

Biao Ma

Ben Draper

Ekaterini Kotsopoulou

Neil Chaplin

Evangelia Kokalaki

Ryan Trowbridge

Edward Hodgkin

John Anderson

Wen Chean Lim

Vijay Peddareddigari

Richard Beswick

Ben Grimshaw

Persis Amrolia

Gordon Weng-Kit Cheung

Sara Ghorashian

Gordon Cheung

Anne Kramer

Brian Philip

Jonathan Fisher

John Short

Lukas Stanczuk

Marco Della Peruta

Paulo Fernandes

Hanna Kymalainen

Vania Baldan

Christian Itin

Kenth Gustafsson

Anna Bulek

James Faulkner

Carlotta Petticone

Emma Chan

Ana Margarida Neves

Adam Badar

Louise Kiru

Mark Lythgoe

Adrien Peters

Maria Stavrou

Evangelina Kokalaki

The present invention provides a chimeric antigen receptor (CAR) which binds a low density target antigen, which comprises a Fab antigen binding domain. The invention also relates to cells expressing such a CAR and their use in the treatment of disease.

Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptors

The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.

Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface

The present invention provides a T cell which expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR), wherein the CAR comprises: an antigen binding domain; a transmembrane domain; and a co-stimulatory intracellular signalling domain; wherein the intracellular signalling domain provides a co-stimulatory signal to the T cell following binding of antigen to the antigen binding domain.

T cell which expresses a gamma-delta t cell receptor (TCR) and a chimeric antigen receptor (CAR)

The present invention provides a variant antigen-binding domain which comprises at least one mutation in the VH domain compared to a reference antibody and which displays an increased affinity for TRBC2 over the reference antibody. It further provides an antibody, a chimeric antigen receptor (CAR), and a bispecific T-cell engager (BiTE), a cell which comprises said CAR, and a conjugate comprising said variant antigen-binding domain or said antibody. Additionally, it provides medical uses, diagnostic methods and methods of personalised medicine that exploit the products of the invention.

Binding domain

The present invention relates to a cell which comprises; (i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (ii) a chimeric TNF receptor (TNFR) which comprises (a) a binding domain which is capable of binding a TNFR ligand; and (b) a TNFR signalling domain.

Cell comprising a chimeric antigen receptor or a transgenic T-cell receptor and comprising a chimeric TNF receptor

There is provided method for making a cell composition which comprises step of transducing a population of cells with a mixture of at least two viral vectors, wherein at least one vector comprises a nucleic acid sequence which encodes a chimeric antigen receptor (CAR); and wherein at least one vector comprises a nucleic acid encoding an activity modulator which modulates the activity of the CAR, of a cell expressing the CAR, or of a target cell. There is also provided a cell composition made by such a method and its use in the treatment of diseases such as cancer.

Compositions and methods comprising engineered chimeric antigen receptor and modulator of CAR

The present invention provides a chimeric antigen receptor (CAR) which specifically binds CD79 as well as a nucleic acid sequence and a vector encoding the CAR. It further provides a cell which expresses the CAR at the cell surface.

CD79-specific chimeric antigen receptor

The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to a ligand selected from a tumour secreted factor, a chemokine and a cell-surface antigen; and (ii) a cytokine receptor endodomain.

Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof

The invention relates to protein-based T-cell receptor knockdown, and its use in T-cell therapies.

Protein-based T-cell receptor knockdown

The present invention provides a chimeric antigen receptor (CAR) comprising a CD21-binding domain, a transmembrane domain and an intracellular domain.

Chimeric antigen receptor

The present invention relates to a cell comprising a chimeric antigen receptor (CAR) and a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.

Cell

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

Methods

The present invention provides a chimeric antigen receptor (CAR) which binds a target antigen having a bulky extracellular domain, wherein the CAR comprises a Fab antigen binding domain. The present invention also provides nucleic acid sequences and constructs encoding such a CAR, cells expressing such a CAR and their therapeutic uses.

Growing community of inventors

London, United Kingdom

Martin Pulé